UCP2 inhibition eliminates pancreatic β cell autoinflammation in T2DM with islet-mitochondrial sequential targeting...

Area of Science:

• Endocrinology
• Molecular Biology
• Nanomedicine

Background:

• Pancreatic beta-cell dysfunction and loss are central to type 2 diabetes mellitus (T2DM).
• Autoinflammation significantly contributes to T2DM pathogenesis, but its molecular drivers in beta cells are not fully understood.
• STING (stimulator of interferon genes) is found to be upregulated in T2DM beta cells.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying beta-cell autoinflammation in T2DM.
• To investigate the role of uncoupling protein 2 (UCP2) and interleukin-1β (IL-1β) in T2DM-associated beta-cell autoinflammation.
• To develop and evaluate a novel nanomedicine for targeting beta-cell mitochondria and inhibiting UCP2 activity.

Main Methods:

• Investigated the expression of STING in T2DM beta cells.
• Characterized the role of the UCP2/mtDNA/STING axis in IL-1β-induced beta-cell autoinflammation.
• Designed and synthesized Mito-G, a genipin- and glycine-based nanomedicine for UCP2 inhibition.
• Assessed the in vivo efficacy of Mito-G in targeting beta-cell mitochondria and reducing autoinflammation.

Main Results:

• Interleukin-1β (IL-1β) was shown to induce beta-cell autoinflammation via the UCP2/mtDNA/STING pathway in T2DM.
• STING levels were significantly elevated in T2DM beta cells.
• The developed nanomedicine, Mito-G, effectively targeted beta-cell mitochondria and inhibited UCP2 activity in vivo, reducing autoinflammation.

Conclusions:

• The UCP2/mtDNA/STING axis represents a critical pathway for beta-cell autoinflammation in T2DM.
• Mito-G demonstrates a promising therapeutic strategy for T2DM by specifically targeting and inhibiting UCP2 in beta-cell mitochondria.
• This approach offers a novel paradigm for treating T2DM by addressing beta-cell autoinflammation.